Grey Wolf Therapeutics

The company develops antigen modulation treatments that alter how cells appear to the immune system by changing the T cell signaling cascade. Its pipeline includes oral ERAP1 inhibitors designed to treat various solid tumor types and autoimmune disorders. These therapies are currently being evaluated in Phase 1/2 clinical trials to address immune dysfunction in oncology and autoimmunity.